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Summary
Heparan sulfate (HS) is present on the surface of endothelial and surrounding tissues in large
quantities. It plays important roles in regulating numerous functions of the blood vessel wall,
including blood coagulation, inflammation response and cell differentiation. HS is a highly sulfated
polysaccharide containing glucosamine and glucuronic/iduronic acid repeating disaccharide units.
The unique sulfated saccharide sequences of HS determine its specific functions. Heparin, an
analogue of heparan sulfate, is the most commonly used anticoagulant drug. Because of its wide
range of biological functions, HS has become an interesting molecule to biochemists, medicinal
chemists and developmental biologists. Here, we summarize recent progress towards understanding
the interaction between heparan sulfate and blood coagulating factors, the biosynthesis of
anticoagulant heparan sulfate and the mechanism of action of heparan sulfate biosynthetic enzymes.
Further, knowledge of the biosynthesis of HS facilitates the development of novel enzymatic
approaches to synthesize HS from bacterial capsular polysaccharides and to produce polysaccharide
end products with high specificity for the biological target. These advancements provide the
foundation for the development of polysaccharide-based therapeutic agents.
Introduction
Heparin is a commonly used anticoagulant drug with annual sale close to $3 billion worldwide.
Heparin is an analog of heparan sulfate (HS), a unique class of macromolecule that is widely
expressed on the cell surface and in the extracellular matrix. HS is a highly sulfated
polysaccharide consisting of the repeating disaccharide unit of 1→4-linked glucosamine and
glucuronic/iduronic acid that may contain sulfo groups. A large body of evidence has
demonstrated that this highly sulfated polysaccharide plays roles in regulating embryonic
development, inflammatory responses, assisting viral and bacterial infections as well as blood
coagulation (1–5). Under physiological pH, the sulfo groups exhibit considerable negative
charges that influence binding properties to more than one hundred proteins. Thus, HS is a
molecule with a high density of information and significant potential for therapeutic
applications. Understanding the mechanism employed by HS to regulate a specific biological
process could aid the development of polysaccharide-based therapeutic agents with anticancer
and antiviral activities as well as improve the pharmacological drug properties of anticoagulant
heparin.
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It is believed that HS achieves its selectivity by interacting with unique protein effectors to
modulate the activities of these effectors. Decoding the nature of the interactions between HS
and associated proteins has attracted considerable interest to delineate the involvement of HS
in these important biological functions at the molecular level(6,7). The prevailing hypothesis
is that a HS polysaccharide with specific sulfation patterns determines the binding affinity and
the extent of the activation of a target protein. Our laboratories focus on understanding the HS
biosynthetic pathway via biochemical and structural biology methods. In this review, we
summarize recent developments regarding aspects of the biosynthesis of anticoagulant HS, the
interaction of anticoagulant HS with thrombin and antithrombin, the interaction of HS and its
biosynthetic enzymes and enzyme-based synthesis of HS. The interaction between HS and
growth factors represent another important arena of HS research: the regulation of embryonic
development, angiogenesis and cancer growth. These topics have been reviewed by several
groups, and they are beyond the scope of this article (8,9).
The interactions of HS and blood coagulating factors
The blood coagulation pathway is composed of a cascade of proteolytic reactions ultimately
generating fibrin thrombi. The proanticoagulant activity of this cascade is balanced by several
natural anticoagulant mechanisms. Binding of HS to antithrombin (AT) represents the most
important of these mechanisms. HS achieves its anticoagulant activity by interacting with AT,
which then undergoes a conformation change, with the generation of the active form of AT
that inhibits blood coagulation factors Xa and thrombin (IIa). Factor Xa or thrombin binding
to AT results in cleavage of the P1-P1′ scissle bond in the reactive center loop (RCL) loop
trapping the coagulant protease in a covalently bound in-active intermediate with the AT
molecule(10–12).
HS is found on the surface of endothelial cells. This suggests a physiologically relevant role
in regulating levels of anticoagulant activity within the blood vessel. Pharmaceutical heparin
is a product of mast cells that is isolated from porcine intestinal tissue with a stronger
anticoagulant activity than endothelial HS. Heparin is considered a specialized form of HS
with higher levels of sulfation per saccharide unit and iduronic acid content. For example, HS
contains about 0.6 sulfo groups per disaccharide unit, while heparin contains 2.6 sulfo groups.
Further, about 40% of uronic acid in HS is iduronic, while 90% uronic acid in heparin is
iduronic. Heparin has remained the drug of choice for the treatment of arterial and venous
thrombotic disorders for more than a decade (13). This is largely due to: heparin is the only
drug that inhibits the activities of both factor Xa and thrombin; heparin has a rapid anticoagulant
response; the excessive anticoagulant activity of heparin is reversible by protamine (14). A
major side effect of purified heparin, however, is thrombocytopenia. This condition is due to
the induction of antibodies against the complex of platelet factor 4 and heparin (15). The
development of a new generation of heparin-based anticoagulant drugs with reduced side
effects remains a high priority.
Structure and anticoagulant activity relationship
Only a fraction of HS binds to AT and exhibits anticoagulant activity. About 1–10% of the HS
isolated from tissues binds to AT, while about 30% of pharmaceutical heparin binds to AT,
suggesting that AT recognizes a unique structure of HS. Structural and functional studies have
revealed that a short pentasaccharide domain of HS is critical for binding to AT (12,16). Based
on the structure of the AT-binding pentasaccharide, a new synthetic pentasaccharide
anticoagulant under the trade name of Arixtra has been approved by FDA(17). However, the
pentasaccharide unit only inhibits the activity of factor Xa mediated by AT. A much larger
oligosaccharide is required to exhibit complete anti-thrombin activity (18,19).
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Selectivity for HS by protein binding partners stems from a number of different structural
variables that affect the overall charge and conformation. The positions of sulfo groups and
the length of the oligosaccharide are essential. In addition, the three dimensional positions of
these sulfo groups can be affected by rotation around glycosidic linkage as well as through
changes in ring conformation. Although GlcUA and GlcNAc are typically found in the 1C4 “
chair” conformation, IdoUA is capable of being in either the 1C4 or 2S0 “skew-boat” orientation
(20,21). Multiple conformations of the IdoUA units can present the sulfates on the surface of
the HS in different arrangements such that the HS can have a variety of different structural and
electrostatic properties that help to optimize protein interactions with the sulfates as well as
optimize van der Waals surface contacts with the protein for increased substrate specificity.
The structural requirement for HS binding to AT was proved by chemically synthesizing a
series of pentasaccharides with various combinations of sulfo groups and carboxyl groups
(17). Removal of certain sulfo or carboxyl groups significantly compromised the binding
affinity to AT, suggesting that these groups are critical (Figure 1A) (22). One of the critical
motifs involved in binding to AT is the sulfation at the 3-OH position of this saccharide. Indeed,
a pentasaccharide ( Figure 1A) that lacks the 3-O-sulfo group from unit C has a decreased
binding affinity to AT by nearly 20,000-fold (22). Functional and structural studies
investigating the interaction of HS with AT thus reveal a convincing example for demonstrating
that a specific sulfated saccharide sequence controls the anticoagulant activity.
The necessary size for an oligosaccharide to inhibit thrombin activity is much longer (14–20
saccharides) than the pentasaccharide that is required to bind AT and inhibit factor Xa(23). A
synthetic hexadecasaccharide (SR123781) that displays excellent anticoagulant activity
against thrombin in vitro and in vivo has been produced (20). This oligosaccharide consists of
an AT-binding domain, a nonsulfated linker region and a thrombin-binding domain (Figure
1B). The structural requirement for binding of this oligosaccharide to thrombin, a cluster of
sulfated saccharide units, appears to be less selective than for AT. Petitou and colleagues proved
that the order of the three domains is essential for thrombin inhibition (19). Namely, the AT-
binding domain is positioned at the reducing end of the nonsulfated linker, and the thrombin-
binding domain at the nonreducing end of the linker. It should be noted that the synthesized
hexadecasaccharide is not a HS, rather a HS mimetic carrying sulfo groups. Several structural
differences between a native HS oligosaccharide and the synthetic hexadecasaccharide are
noted (Figure 1B). This HS mimetic contains methylated hydroxyls and glucose instead of
glucosamine at the AT-binding domain (S12–S16). These glucose units contain 2-O-sulfo
groups instead of the N-sulfo groups as would be present on glucosamine units. In addition,
highly sulfated glucose units (thrombin-binding domain, S1–S5) mimic the binding of -
IdoUA2S-GlcNS6S- in heparin, provided that the binding of HS to thrombin requires only
highly sulfated saccharide units and thus is non-specific. Despite structural differences, the
binding of AT and thrombin to this hexadecasaccharide appears to mimic the interaction of
AT, thrombin and HS (12). Chemically synthesized HS hexadecasaccharides have not been
reported.
Crystal structure of ternary complex AT/Thrombin/hexadecasaccharide
Details of the molecular interactions have been ascertained from X-ray crystal structures of
the binary complex of AT/HS as well as from ternary complexes of AT/thrombin and
SR123781 (10,12,16). These structures have revealed interactions between AT and heparin
and heparin and thrombin that account for the increased level of inhibition of thrombin by AT
in the presence of heparin (Figure 2).
Numerous contacts between the sulfo and carboxyl groups of the oligosaccharide with the
proteins were observed in the ternary complex, in particular in the region of AT and the AT-
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binding domain of the hexadecasaccharide (Figure 2). All of the saccharide units in the AT-
binding domain are in the chair conformation with the exception of the iduronic acid (S15) at
the reducing end, which is present in the “skew-boat” conformation. There is a kink in the
domain between this iduronic acid and the neighboring glucose (S14) that contains the specific
3-O-sulfo group. Indeed, the skew boat conformation of this iduronic acid unit is essential for
binding to AT as demonstrated by Das and colleagues (24). The interactions between AT and
HS involve the sulfo groups on the glucosamine equivalent glucose molecules at the 2,3 and
6 position as well as with carboxylate groups from the uronic acid saccharides. These
interactions confirm the conclusions from the biochemical studies (Figure 1A) (reference
ternary structure papers). The functional groups that form interactions with AT are the 2-O-
sulfo of S16, the carboxylate from S15, the 2-O-sulfo and 3-O-sulfo groups from S14, the
carboxylate from S13, and the 6-O-sulfo group from S12. These specific interactions involve
both side chain and backbone interactions with AT. The critical 3-O-sulfo group on S14 for
AT binding is within hydrogen bonding distance to two lysines and one asparagine side chain.
Given the numerous interactions between the pentasaccharide and AT, it is unclear why the 3-
O-sulfo group from S14 is critical to binding. One possibility may be that locking this position
down leads to the kink in the pentasaccharide with subsequent optimization of van der Waals
contacts and ionic interactions with AT.
Biosynthesis of anticoagulant HS
Biosynthetic pathway
Cellular HS is present in the form of HS proteoglycan, which consists of a core protein and
polysaccharide side chains. HS polysaccharide is attached to the core protein through a serine
residue. The core protein functions as a carrier of the HS chains on the cell surface and in the
extracellular matrix. Although the binding of HS polysaccharide side chains with protein
effectors is believed to result in specific biological functions, the expression of core proteins
plays a critical role in temporal and spatial regulation of cellular HS (25). The biosynthesis of
HS is performed by a complex pathway involving chain elongation and multiple modification
steps (Figure 3). Synthesis is initiated with addition of a linkage region domain (LRD) to a
specific Ser residues on the protein followed by elongation steps to generate the unsulfated and
unepimerized polysaccharide backbone consisting of GlcUA-GlcNAc disaccharide repeats
(26,27).
After chain elongation, the polymer is modified by a series of sulfotransferases and a C5
epimerase (Figure 3). The first modification is N-sulfonation to form the N-sulfo glucosamine
unit by N-deacetylase/N-sulfotransferase (NDST). NDST is a dual function enzyme that
catalyzes the removal of the acetyl group from a GlcNAc residue and the transfer of a sulfo
group to the amino group of the “deacetylated” unit. The C5-epimerase converts the
neighboring GlcUA on the nonreducing side to an IdoUA unit. The chain modification proceeds
with 2-O-sulfonation at the iduronic acid (or to a lesser extent at a GlcUA), 6-O-sulfonation
at the glucosamine and 3-O-sulfonation at the glucosamine. These modifications are catalyzed
by 2-O-sulfotransferase (2-OST), 6-O-sulfotransferase (6-OST), and 3-O-sulfotransferase (3-
OST), respectively (Figure 3).
Biosynthesis of a polysaccharide with defined sequences
The mechanism for regulating synthesis of polysaccharides with defined saccharide sequences
is essentially unknown because the synthesis is not a template-driven process. Nevertheless, it
appears that structures of HS from a single cell line are consistent between generations,
suggesting that the synthesis of HSs with unique saccharide sequences are genetically
controlled (28). In addition, synthesis of specific saccharide sequences can be regulated by the
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expression levels of specialized biosynthetic enzymes and the accessibility of the unique
substrates for those specialized biosynthetic enzymes. These observations have led to a widely
accepted hypothesis: that the overall sulfation pattern of HS is dictated by the substrate
specificities of HS biosynthetic enzymes. However, the detailed regulation of the sulfation
pattern on a polysaccharide are not well understood.
The biosynthetic enzymes exhibit the substrate specificities at two different levels: the regio-
selectivity of the residue to be modified (the monosaccharide level) and the saccharide
structures around the modified residue (at the oligosaccharide level). The regio-selectivity for
a given HS sulfotransferase is nearly exclusive (29–32). For example, 2-OST recognizes an
iduronic acid (or a glucuronic acid) residue, and specifically transfers the sulfo group to the 2-
OH position to form IdoUA2S (or GlcUA2S).
The best evidence of substrate specificities at the oligosaccharide levels is demonstrated by
the fact that different isoforms recognize unique sulfation patterns around the modification site
(33). HS biosynthetic enzymes are present in multiple isoforms with the exception of 2-OST
and C5 epimerase. NDST is present in four different isoforms, 6-OST is present in three
different isoforms and 3-OST in seven. The isoforms have slightly different substrate
specificities and unique tissue specific expression patterns (34–37). It has been hypothesized
that cells regulate expression levels of different isoforms of the biosynthetic enzyme in order
to synthesize HS with defined saccharide sequences to achieve unique biological functions
(38). Indeed, 3-OST isoforms are essential for the synthesis of heparin/HS with a variety of
saccharide sequences that exhibit different substrate specificities, and the products display
distinct biological functions as described in the section below. 6-OST isoforms are important
for generating HS responsible for fibroblast growth factors and fibroblast growth factor
receptor complex formation, although the substrate specificities among 6-OSTs are not
experimentally distinguishable (39,40). The substrate specificities of NDST isoforms are more
difficult to determine with current techniques, and thus, are largely unknown.
Regulation of the biosynthesis of anticoagulant HS
The key control of anticoagulant HS synthesis in vivo by cells is regulation of the expression
level of HS 3-O-sulfotransferase isoform 1 and isoform 5 (3-OST-1 and 3-OST-5) (32,34). 3-
OST’s transfers the sulfo group to the 3-OH position of a glucosamine unit to form a 3-O-
sulfated glucosamine. The detailed substrate specificities of 3-OST isoforms are described
below. Overexpression of 3-OST-1 and 3-OST-5 in cells significantly elevates the level of
anticoagulant HS (41,42). The existence of multiple isoforms may explain why 3-OST-1
knockout mice failed to produce thrombotic phenotypes (41).
Substrate specificities and mechanism of action of 3-OST isoforms
Substrate specificities of 3-OST isoforms
HS 3-OST is present in seven isoforms, including 3-OST-1, -2, -3A, 3B, -4, -5, and 6 (33,34,
43). These enzymes catalyze the transfer of a sulfo group from the sulfo donor, 3′-
phosphoadenosine-5′-phosphosulfate (PAPS), to the 3-OH position of a glucosamine unit. The
amino acid sequences of the different isoforms have greater than 60% homology in the
sulfotransferase domains. The isoforms transfer the sulfo group to the glucosamine residues
that are linked to different saccharide units at the nonreducing end. The modifications
predominately fall into three types (Figure 4). First, the sulfo group is transferred to the
glucosamine unit that is adjacent to an unsulfated glucuronic acid (GlcUA). This type of
modification is carried out by 3-OST-1. Second, the sulfo group is transferred to the
glucosamine unit that is adjacent to a 2-O-sulfo iduronic acid (IdoUA2S). This type of
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modification is performed by 3-OST-2, -3A, -3B, -4, and -6. Among these, 3-OST-3A and 3-
OST-3B have nearly identical amino acid sequence in the sulfotransferase domain, and thus,
3-OST-3 represents both 3-OST-3A and 3-OST-3B. Third, the sulfo group is transferred to the
glucosamine unit that is adjacent to GlcUA, IdoUA and IdoUA2S. This type of modification
is carried out by 3-OST-5 (44).
The unique substrate specificities of different 3-OST isoforms endow HS with distinct
biological functions. As described above, 3-OST-1 and 3-OST-5 carry out critical 3-O-
sulfation that permits the resultant HS binds to AT and exert anticoagulant activity. On the
other hand, other 3-OST isoforms, including 3-OST-2, -3, -4, -5, and -6, carry out the critical
3-O-sulfation that generates HS with activity that promotes the infection of herpes simplex
virus type 1 (HSV-1) (43,45). HS modified by these isoforms interacts with herpes virus
envelope glycoprotein gD and serves as an entry receptor for the virus.
Crystal structures of 3-OST-1 and 3-OST-3
Because 3-OSTs play a critical role in controlling the biosynthesis of anticoagulant HS and
unique substrate specificities among the isoforms, we investigated the mechanism of 3-OSTs
using a structural biology approach coupled with site-directed mutagenesis(46,47). From these
studies, several key amino acid residues have been identified that contribute to the interactions
with the sulfo donor PAPS, as well as with polysaccharide substrates.
The crystal structure of 3-OST-1 in complex with PAP was solved at 2.5 Å. In addition, a
ternary complex of 3-OST-3/PAP/tetrasaccharide substrate was solved at 1.9Å (46,47). We
have found that 3-OST-1 and 3-OST-3 have very similar overall structure. Here, we focus our
attention on describing the structure of 3-OST-3/PAP/tetrasaccharide (Figure 5A and 5B). The
tetrasaccharide used in this study binds in a positively charged cleft. As seen in heparin binding
to AT, a kink is induced by the protein between the two central residues I2 and G3 of the
tetrasaccharide. The G1 residue forms interactions with the protein via the N-sulfo group and
a bound sodium, as well as with the 3-hydroxyl. The I2 residue is found in the “skew-boat”
conformation and forms interactions with its carboxylate group and 3-hydroxyl. The substrate
residue G3 is oriented in a catalytically relevant position with the 3 hydroxyl acceptor
positioned 5 Å from the 5′-phosphate of the leaving group PAP and within hydrogen bonding
distance of the proposed general base E184. In addition, the N-sulfo group is hydrogen bonded
to a backbone amide. At the nonreducing end of the tetrasaccharide is the terminal uronate
residue (U4) with an unsaturated 4,5 carbon bond which results from the polysaccharide
cleavage by a heparin lyase. This residue dictates substrate specificity between 3-OST-1 and
3-OST-3 and forms ionic interactions with both the 2-O-sulfo group and the carboxylate group
as well as a possible interaction with the 3′ hydroxyl An unsulfated glucuronic acid at this
position (as is the case for the 3-OST-1 substrate) would likely have a different ring
conformation and thus likely would not form the same interactions. Mutations have been made
in these regions of 3-OST-3 and 3-OST-1 to support the conjecture that these residues
determine substrate specificity. By understanding these subtle differences, we may be able to
alter the substrate specificity of these enzymes to create more specific enzymes or novel
sulfation patterns on heparin to improve the requirements for use of HS as therapeutic agents.
For example, structure-activity studies suggest that an extra 3-O-sulfo group at unit E (Figure
1A) improves the binding affinity to AT nearly 100-fold (18). A pentasaccharide consisting of
two 3-O-sulfated glucosamine units has not yet been isolated from natural sources. The addition
of a 3-O-sulfate group using genetically modified 3-OST enzymes could increase the
specificity of the synthesized HS for AT.
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Chemoenzymatic synthesis of HS with biological activities
Synthesis of HS oligosaccharides has proved to be successful for the development of synthetic
versions of HS-based anticoagulant drugs (17). This endeavor is largely based on the fact the
side effects of heparin drugs stem from the structural heterogeneity of the polysaccharide
(17).
Although chemical synthesis has been the major route to obtain structurally defined heparin
oligosaccharides, total chemical synthesis is time consuming and costly. Further, chemical
synthesis of non-analog heparin and HS oligosaccharides, larger than hexasaccharides, is
extremely difficult, if not impossible, based on currently available methods for carbohydrate
synthesis. While a number of groups continue to pursue the synthesis of heparin (48–50), it is
likely that chemical synthesis alone will be incapable of generating most larger oligosaccharide
structures. The application of HS biosynthetic enzymes for generating large heparin and HS
oligosaccharides with desired biological activities offers a promising alternative approach.
Attempts to synthesize HS using biosynthetic enzymes have been reported. Although it is
unclear whether the enzymatic approach synthesizes structurally defined polysaccharides, this
method generates products with desired anticoagulant activity. Kuberan and Rosenberg utilized
this approach to synthesize HS containing AT binding sites, with anticoagulant activity (51–
53). While this approach demonstrated for the first time the feasibility of enzymatic synthesis
of HS, only microgram amounts of product were generated, making extensive biological
studies impossible. Recently, Lindahl and colleagues reported an alternative chemoenzymatic
approach for the synthesis of anticoagulant heparin from heparosan, an E. coli K5 capsular
polysaccharide (54). This method utilized the C5 epimerase to convert D-glucuronic acid
(GlcUA) to L-iduronic acid (IdoUA), followed by the chemical persulfonation and finally
selective desulfonation. While this approach affords gram quantities of a heparin-like
polysaccharide with anticoagulant activity, unnatural saccharide units, such as 3-O-sulfo-D-
glucuronic acid, are present in the product, suggesting a limitation in the selectivity of chemical
sulfonation/desulfonation in HS synthesis. To this point, an effective approach for the synthesis
of structurally defined large oligosaccharides is not yet available.
Following the same strategy we have developed an efficient approach to synthesize the HS
with desired biological activities in multi-milligram scales. To achieve enzymatic synthesis of
HS at a practical pharmaceutical level on a large scale, two obstacles need to be overcome; the
availability of large amount of HS sulfotransferases and the inhibition effect of 5′-
phosphoadenosine 3′-phosphate (PAP), the desulfated product of PAPS. A proof of principle
study has been recently published using completely desulfated and N-sulfated heparin (1) as a
starting material (Figure 6) to conduct the O-sulfonation reactions (55). First, highly active HS
O-sulfotransferases were expressed in E. coli, in order to provide sufficient quantities of
sulfotransferases. Second, the sulfotransfer reactions were coupled with the PAPS regeneration
system that was developed by the Wong group(56). This strategy eliminates the inhibition
effect of PAP. The PAPS regeneration system utilizes arylsulfotransferase IV, which can
converts PAP to PAPS as illustrated in Figure 6B. In addition, the PAPS regeneration system
utilizes the p-nitrophenol sulfate PNPS as the sulfo donor and requires only catalytic amounts
of PAP, thereby reducing the cost of synthesis by more than 1000-fold (56). Immobilized
enzymes are used in this approach for reuse and improved thermal stability of the HS
sulfotransferases. Thus the protocol can be efficiently scaled up. This method is capable of
generating milligram quantities of specifically sulfated polysaccharide for desired biological
activities: these include the anticoagulant activity as measured by the anti-Xa and anti-thrombin
activities (compounds 5 and 8), the activity in triggering FGF/FGF receptor signaling
(compounds 4a and 4b) and binding to herpes simplex virus glycoprotein D (compound 6).
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In addition to the anticoagulant activity of HS, many novel biological functions have emerged
in recent years. These functions include roles of HS in regulating cancer growth, assisting viral
and bacterial infections and inflammatory responses. Indeed, a low molecular weight heparin
mimetic, PI88, is under phase II clinical trial to treat herpes simplex viral infections (57). In
addition, PI88 also potentially serves as an anticancer drug, inhibiting the activity of heparanase
in facilitating tumor metastasis (58). Knowledge of HS/heparin interactions with blood
coagulating factors and how the biosynthesis of anticoagulant HS is performed will provide a
model system for investigating the roles of HS in other related biological processes. It is clear
that a chemoenzymatic approach is a viable method for generating the polysaccharides with
different sulfation patterns and biological functions. The next challenge for HS/heparin
research is the development of a technique to prepare “recombinant polysaccharides” with
more precise structures so as to achieve high functional selectivity. The improved
understanding of the regulation of HS biosynthesis and/or simplified synthetic techniques will
help to achieve this goal. In the coming years of the glycomics era, continuing efforts on in
HS/heparin research will likely lead to novel therapeutic agents.
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Figure 1. Structures of AT-binding domain and chemically synthesized hexadecasaccharide with
anti-IIa activity
Panel A shows the structure of AT-binding pentasaccharide. The critical sulfo and carboxylate
groups for the binding of AT in the pentasaccharide are circled. The name of individual
saccharide unit is below each unit. Panel B shows the structure of the synthetic
hexadecasaccharide (SR-123781). The AT-binding domain, nonsulfated linker and the
thrombin-binding domain are indicated. Reducing and nonreducing ends are also indicated.
S1, S2, …, S16 define the position of the saccharide units.
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Figure 2. Heparin analog binding in the AT/thrombin complex
Crystal structure of the ternary complex between AT(cyan), thrombin(pink), and a synthetic
hexadecasaccharide SR-123781(green). The critical 3-O-sulfo group for effective AT binding
is labeled with an asterisks and an arrow locates the kink formed in the heparin analog by AT
binding. The reactive center loop (RCL) of AT is shown in blue along with residue R393 of
AT bound to the active site of thrombin (This figure was created using the PDB coordinates
1TB6 with the programs Molscript and Raster3D (59,60).).
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Figure 3. HS biosynthetic pathway
This scheme shows the sequential enzymatic modifications that occur after chain elongation.
LRD represents linkage region domain.
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Figure 4. Substrate specificity of 3-OST isoforms
The reactions catalyzed by 3-OST-1 and 3-OST-3 are shown. 3-OST-1 transfers the sulfo group
from PAPS to the 3-OH position of a glucosamine unit (GlcNS±6S) that is linked to a
glucuronic acid unit (GlcUA), thereby forming the 3-O-sulfated HS containing GlcUA-
GlcNS3S±6S (an anticoagulant HS). 3-OST-3 transfers the sulfo group to the 3-OH position
of a glucosamine unit (GlcNH2±6S) that is linked to a 2-O-sulfo iduronic acid unit (IdoUA2S),
thereby forming the 3-O-sulfated HS containing IdoUA2S-GlcNH23S±6S (an entry receptor
for herpes simplex virus type 1 (HSV-1). R represents a proton (−H) or a sulfo group
(−SO3−).
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Figure 5. 3-OST-3a/PAP/tetrasaccharide complex
A) crystal structure of 3OST-3A in complex with PAP(blue) and a tetrasaccharide HS molecule
(green). B) Superposition of PAPS onto PAP in the active site of the 3OST-3a crystal structure.
This figure displays the relative orientation of the acceptor 3-hydroxyl to the sufo group being
transferred from PAPS. Side chains that are involved in binding the tetrasaccharide are shown.
A sodium ion involved in binding is pictured in pink. The location of the kink, in the
polysaccharide, is indicated by an arrow. C) Figure displaying side chain with specific
functional groups of the bound tetrasaccharide. Hydrogen bonds are indicated by dashed lines.
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Figure 6. Pathways for Synthesis of su lfated polysaccharides and the PAPS regeneration system
Panel A shows the stepwise enzymatic synthesis of sulfated polysaccharides using HS
sulfotransferases. Compounds 4a and 4b are prepared by inverting the order of sulfation steps:
4a is prepared by incubating compound 1 with 2-OST followed by 6-OST, whereas 4b is
prepared by incubating compound 1 with 6-OST followed by 2-OST. Panel B shows the
reaction catalyzed by arylsulfotransferase IV (AST-IV) to generate PAPS. R represents −H or
−SO3.
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